Hematology/Oncology

Top Story

FDA grants breakthrough drug designation to Lenvima for advanced RCC

July 29, 2015

The FDA granted breakthrough drug designation to lenvatinib for the treatment of patients with advanced or metastatic renal cell carcinoma who received prior treatment with at least one VEGF-targeted therapy, according to a press release from the drug’s manufacturer.

Lenvatinib (Lenvima, Eisai Inc), a multiple receptor tyrosine kinase inhibitor, is currently approved for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.

In the Journals

Health care spending expected to increase over decade, but at historically low rate

July 29, 2015
Due to expanded health insurance coverage from the ACA, as well as the aging population and economic growth, health care spending is projected to increase at a rate of…
In the Journals

Lymphoma survivors face increased risk for cardiac problems after HSCT

July 29, 2015
Left ventricular systolic dysfunction and heart failure occurred more frequently than previously reported in adult survivors of lymphoma who underwent autologous…
In the Journals

What are the benefits vs. risks of contralateral prophylactic mastectomy?

July 29, 2015
Women diagnosed with cancer in one breast often decide to undergo contralateral prophylactic mastectomy — or the removal of the other cancer-free breast — as…
In the Journals

Oncologists criticize high drug costs, propose cost-cutting measures

July 28, 2015
Over 100 U.S. oncologists have issued a statement deriding the high cost of cancer drugs and calling for new regulations to mitigate expenses.Authors of the statement…
More News Headlines »
CME
Immunotherapy Updates 2015: FOCUS on NSCLC

Immunotherapy Updates 2015: FOCUS on NSCLC

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for…
More »
Meeting News Coverage Video
VIDEO: 'Care paths' may help manage rising cancer costs

VIDEO: 'Care paths' may help manage rising cancer costs

June 19, 2015
CHICAGO — Brian Bolwell, MD, chairman of Taussig Cancer Institute at Cleveland Clinic, discusses an abstract on…
More »
Tailored Therapies for Myelodysplastic Syndromes

Tailored Therapies for Myelodysplastic Syndromes

This activity is supported by an educational grant from Celgene Corporation.

Myelodysplastic syndromes (MDS) represent a group of myeloid clonal hemopathies with heterogeneous clinical…
More »
morganatic-roan
morganatic-roan